Essential Thrombocythemia CALR Mutation: Prognosis & Risk

People with essential thrombocythemia (ET) who carry a CALR mutation generally face a more favorable outlook than those with the more common JAK2 mutation, particularly when it comes to blood clots. But “more favorable” comes with real caveats that depend on the specific type of CALR mutation, how large the mutant clone is, and whether additional genetic changes are riding along. The story is more layered than a simple good-news-bad-news split, and getting the details right matters for treatment decisions and long-term monitoring.

How CALR Mutations Fit Into ET

ET is driven by one of three “driver” mutations in most patients. The JAK2 V617F mutation is the most common, found in roughly a third to two-thirds of ET cases depending on the cohort studied. The MPL mutation accounts for a smaller slice, and CALR mutations fill in much of the remainder. A landmark 2013 study in the New England Journal of Medicine identified CALR mutations in about two-thirds of ET patients who lacked JAK2 or MPL changes, effectively closing a diagnostic gap that had persisted for years.¹ A meta-analysis covering studies from 2000 to 2018 found that CALR mutation frequency in ET ranged from about 13% to 50% across different cohorts.² A small group of patients test negative for all three drivers and are called “triple-negative.”

The mutated calreticulin protein, which in its normal form is a chaperone inside cells, gains an abnormal ability to latch onto and activate the thrombopoietin receptor (MPL). That activation switches on JAK2 signaling even without the normal growth signal, thrombopoietin, being present.³ Laboratory work has confirmed that the mutant CALR protein physically binds MPL and triggers strong, constitutive activation of the JAK-STAT signaling pathway.⁴ So while CALR-mutated ET and JAK2-mutated ET both funnel through the same downstream pathway, the entry point is different, and that distinction shapes the clinical picture.

What CALR-Mutated ET Looks Like Compared to JAK2-Mutated ET

CALR-mutated ET has a recognizable clinical fingerprint. Patients tend to be younger at diagnosis, have higher platelet counts, lower white blood cell counts, and lower hemoglobin levels than their JAK2-positive counterparts. One study directly comparing the two groups found mean platelet counts of roughly 1,079 × 10⁹/L in CALR-mutated patients versus 858 × 10⁹/L in JAK2-positive patients, with leukocyte counts of 9.6 versus 10.9 × 10⁹/L.⁵ The paradox of very high platelets yet fewer complications is one of the defining features of this subtype.

Despite carrying those sky-high platelet numbers, CALR-mutated patients consistently show lower rates of thrombosis. In the same study, total thrombosis rates were about 21% in CALR-mutated patients versus 38% in JAK2-positive patients, and venous thrombosis rates were particularly low.⁵ Research using the IPSET-thrombosis risk scoring system has confirmed that CALR-mutated patients cluster more frequently in the low-risk group and enjoy better thrombosis-free survival than JAK2-mutated patients.⁶

The lower clotting risk is thought to relate partly to the white blood cell difference. Elevated leukocytes, and especially activated white cells, contribute to the prothrombotic state in JAK2-mutated disease. CALR-mutated patients, with their more modest white cell counts, seem to sidestep some of that vascular danger.

Type 1 Versus Type 2 CALR Mutations

Not all CALR mutations behave identically. They cluster into two main categories. Type 1 mutations (a 52-base-pair deletion) and type 2 mutations (a 5-base-pair insertion) together account for the large majority of CALR-mutated ET cases. In one collaborative study of over 1,000 ET patients, about 45% of CALR-mutated cases had type 1 and 39% had type 2, with the remainder carrying rarer variants that generally resemble one type or the other.⁷

The two types have subtly different profiles. The collaborative study found that type 1 was more common in men, while type 2 was associated with younger age at diagnosis and higher platelet counts.⁷ However, these associations have not been perfectly consistent across all cohorts. A separate analysis confirmed the male predilection for type 1 but did not replicate the finding that type 2 had higher platelet counts or younger age.⁸

Where the distinction matters most is in the risk of progressing to myelofibrosis, the scarring of bone marrow that represents a more advanced stage of disease. Type 1 (and type 1-like) CALR mutations appear to carry a higher risk of fibrotic transformation. A large multicenter study identified CALR type 1/type 1-like or MPL mutation as an independent risk factor for progression to myelofibrosis, with a hazard ratio of 3.4.⁹ Meanwhile, type 2 CALR-mutated patients in at least one analysis had longer myelofibrosis-free survival than either type 1 or JAK2-positive patients.⁵

Myelofibrosis Progression and Why Clone Size Matters

An early influential study found no significant difference in myelofibrotic transformation between CALR-mutated and JAK2-mutated ET overall.¹⁰ A meta-analysis also noted only a slight trend toward fibrotic transformation in CALR-mutated ET, without reaching strong statistical significance.¹¹ So the overall risk of myelofibrosis is not dramatically worse for CALR-mutated ET as a whole. The picture shifts when you look at clone burden.

The variant allele frequency (VAF), a measure of what proportion of blood cells carry the mutation, turns out to be a powerful prognostic marker. Research presented at the American Society of Hematology found that patients with a CALR VAF above 60% had a hazard ratio of 2.85 for fibrotic progression compared to those with lower burdens, and over half of those high-VAF patients eventually transformed to myelofibrosis versus only 15% of low-VAF patients.¹² The VAF did not predict thrombosis, bleeding, or leukemic transformation, making it a specifically useful flag for fibrotic risk.

For leukemic transformation, the picture is somewhat reassuring. The meta-analysis found no significant increase in leukemia risk among CALR-mutated ET patients.¹¹ What does increase leukemia risk is the presence of additional “high molecular risk” (HMR) mutations alongside CALR, which brings us to a related concern.

When Additional Mutations Ride Along

CALR-mutated ET rarely exists in a genetic vacuum. Patients can accumulate secondary mutations in genes associated with epigenetic regulation, splicing, or signaling. These HMR mutations have emerged as perhaps the most important modifier of prognosis in CALR-mutated ET, in some analyses mattering more than the CALR allele burden itself. A recent multicenter molecular characterization study found that HMR mutations were an independent predictor of worse overall survival, with a hazard ratio above 2, and were also associated with a higher risk of progression to acute leukemia.¹³

These additional mutations also affect how well patients respond to treatment. In a study of interferon-alpha therapy, patients who carried only the CALR mutation were more likely to achieve deep molecular responses, while those with additional mutations had higher rates of no response or minimal molecular response.¹⁴ This makes next-generation sequencing panels, which test for a broad set of mutations beyond the three main drivers, increasingly relevant for risk assessment in CALR-mutated ET.

Treatment Considerations

Standard treatment for ET centers on reducing the risk of thrombosis and controlling symptoms. Low-dose aspirin is the backbone, and cytoreductive therapy (drugs to lower blood counts) is added for higher-risk patients. The choice of cytoreductive agent is where mutation status starts to influence the conversation.

Interferon-alpha has shown particular promise in CALR-mutated ET. In one study, all CALR-mutated patients achieved a hematologic response on interferon therapy, and the median CALR mutant allele burden dropped substantially, from 41% to 26%. Two patients even achieved a complete molecular response, meaning the mutation became undetectable. By contrast, CALR allele burden did not change significantly in patients treated with hydroxyurea or aspirin alone.¹⁵ This suggests interferon may have a disease-modifying effect beyond just controlling blood counts.

Serial monitoring of CALR VAF can track treatment response over time. In a cohort of 131 patients with serial measurements, complete molecular remission was rare (about 1.5%), but partial molecular responses were achieved in a small fraction, and patients who reached deeper molecular responses were more likely to achieve complete clinical responses as well.¹⁶

Therapies That Target Mutant CALR Directly

One of the most exciting developments in MPN research is the emergence of treatments designed to go after the mutant calreticulin protein itself. Because the mutant protein sits on the surface of abnormal cells (bound to the MPL receptor), it presents a target that normal cells do not share. Researchers are pursuing monoclonal antibodies, bispecific antibodies, cancer vaccines, CAR-T cells, and antibody-drug conjugates aimed at this target.¹⁷

The furthest along is INCA033989, a monoclonal antibody specifically designed to block mutant calreticulin’s oncogenic signaling. Early results from phase 1 trials in CALR-mutated ET patients have been striking. Across dose levels, 73% of patients achieved a complete hematologic response, with rapid and durable normalization of platelet counts. Ninety percent of patients who had follow-up molecular measurements showed a reduction in their CALR mutant allele burden, and about a fifth achieved a reduction of 50% or more. Bone marrow biopsies showed improvement in the abnormal megakaryocyte overgrowth that characterizes ET, with a shift from mutated to normal blood cell production.¹⁸ These are early-phase data and the durability of responses remains to be proven in larger, longer trials, but the concept of selectively eliminating the abnormal clone rather than simply suppressing blood counts represents a genuine shift in how CALR-mutated ET might be managed.

Pregnancy in CALR-Mutated ET

ET often affects people of childbearing age, and CALR-mutated patients tend to be diagnosed younger, making pregnancy management a practical concern. A Mayo Clinic study of 200 pregnancies in ET patients found that aspirin therapy significantly reduced first-trimester pregnancy loss in both JAK2-mutated and CALR-mutated women. Among CALR-mutated patients, the first-trimester loss rate dropped from 43% without aspirin to 8% with it.¹⁹

The study also flagged a concern specific to CALR-mutated pregnancies: a higher rate of maternal hemorrhage, at about 13% compared to 4% in non-CALR cases.¹⁹ This is consistent with a known paradox in ET: extremely high platelet counts can actually cause bleeding rather than clotting, because the excess platelets can absorb and deplete a blood protein needed for normal clot formation. CALR-mutated patients, who tend to carry the highest platelet counts, may be particularly susceptible. Pregnancy management in CALR-mutated ET requires balancing the clear benefit of aspirin against this bleeding tendency, ideally with close hematology involvement.

ET in Children and Young Adults

When ET appears in people under 20, the genetic landscape looks different from adult disease. A systematic review of pediatric and young-adult ET found that only about 25–40% of cases carried any of the three known driver mutations, and CALR mutations specifically were found in only about 10% of young ET patients, making them less common than in adults.²⁰ The majority of young ET patients are triple-negative, which raises the question of whether pediatric ET is even the same disease as the adult version in most cases.

The good news is that pediatric ET in general carries a more benign prognosis, at least within the first few decades. Thrombotic events are rare, and bleeding episodes tend to be minor.²¹ When CALR mutations are found in young patients, they follow the same biological pattern seen in adults: the mutations cluster in JAK2/MPL-negative cases and involve the same exon 9 frameshift changes.²² But because these patients face potentially decades of living with the disease, the very long-term risks of fibrotic progression and clone evolution are largely unknown. Pediatric ET patients are generally managed more conservatively than adults, with adult risk stratification tools fitting only imperfectly.

Symptom Burden and Quality of Life

A question patients often ask is whether having a CALR mutation means they will feel different day to day. Data from the MOST study, a large observational study of real-world MPN patients, suggests that symptom burden is surprisingly similar between CALR-mutated and JAK2-mutated ET. Mean symptom scores on a validated MPN symptom assessment tool were comparable at enrollment and remained essentially unchanged over three years of follow-up. The proportion of patients with elevated white counts, high platelets, or enlarged spleens was also similar between groups at enrollment. In terms of living with ET from a symptomatic standpoint, the mutation type does not appear to create a meaningfully different experience for most patients.

Where the real quality-of-life distinction may emerge is not in baseline symptoms but in the psychological dimension of risk awareness. A CALR-mutated patient told they are at lower thrombotic risk may experience less anxiety around daily activities, while a patient told their specific CALR subtype or high VAF raises their fibrotic risk may carry a different kind of worry. As molecular monitoring becomes more routine and as therapies like INCA033989 potentially offer clone reduction, the ability to track the mutation over time may itself change the patient experience, turning an abstract genetic label into something measurable and modifiable.